🟢 Precigen is trading 4.84% up in after-hours trading as investors digest FDA platform technology designation

Precigen is trading 4.84% higher at $7.80 in after-hours trading as investors digest the FDA’s September 21, 2026 designation of its AdenoVerse immunotherapeutic platform.

• The designation supports reusing manufacturing and preclinical knowledge across future programs, including PRGN-2009, and may reduce development duplication.
• No separate September 23 company announcement was identified; broader markets declined, so the gain appears primarily company-driven.
• Confidence is medium: regulatory news is well supported, but no source directly linked the move to it; extended-hours trading can be thin and volatile.